EPS for Semler Scientific, Inc. (SMLR) Expected At $0.20

October 2, 2018 - By Adrian Mccoy

Semler Scientific, Inc. (OTCMKTS:SMLR) Logo

Analysts expect Semler Scientific, Inc. (OTCMKTS:SMLR) to report $0.20 EPS on October, 30.They anticipate $0.21 EPS change or 2,100.00 % from last quarter’s $-0.01 EPS. SMLR’s profit would be $1.23M giving it 47.88 P/E if the $0.20 EPS is correct. After having $0.19 EPS previously, Semler Scientific, Inc.’s analysts see 5.26 % EPS growth. The stock increased 3.51% or $1.3 during the last trading session, reaching $38.3. About 114,841 shares traded or 183.76% up from the average. Semler Scientific, Inc. (OTCMKTS:SMLR) has 0.00% since October 2, 2017 and is . It has underperformed by 15.62% the S&P500.

Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company has market cap of $235.48 million. The Company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform that performs tests for various chronic diseases, such as respiratory disease, vascular disease, eye disease, bone disease, heart disease, neuropathy, and diabetes. It has a 104.08 P/E ratio. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>